Huntington’s Disease Treatment Market was estimated at USD 380.3 million in 2022 and is poised to reach at 2045.3 million in 2030 anticipated to expand at a compound annual growth rate approx. CAGR of 23.4% for the forecast period of 2023-2030.

Huntington's Disease (HD) is a rare genetic disorder that affects the brain, causing progressive deterioration of both physical and mental abilities. Currently, there is no cure for HD, and available treatments only aim to manage symptoms and improve quality of life for patients.

However, with advancements in medical research and technology, the Huntington's Disease treatment market holds great potential for future developments. Several approaches are being explored to target the underlying cause of HD, which is a mutation in the huntingtin gene.

Get Free PDF Sample Report: https://www.snsinsider.com/sample-request/3029

One promising avenue is gene therapy. Researchers are investigating ways to deliver healthy copies of the huntingtin gene into affected cells to replace the mutated ones. This approach has shown promise in preclinical studies and early-stage clinical trials, offering hope for a potential cure or disease-modifying treatment in the future.

Another area of focus is developing drugs that can suppress or silence the production of mutant huntingtin protein. By targeting this toxic protein, researchers aim to slow down or halt disease progression. Several pharmaceutical companies are actively working These efforts are driven by the urgent need to find effective treatments for neurodegenerative diseases like Huntington's.

KEY MARKET SEGMENTS

By Treatment

·          Symptomatic Treatment

·         Disease-modifying Therapies

By End Use

·         Hospital Pharmacy

·         Retail Pharmacy

·         E-commerce

Major Players Listed in the Report are as Follows:

Neurocrine Biosciences, NeuExcell Therapeutics Inc, H. Lundbeck A/S, Teva Pharmaceutical Industries Ltd, Bausch Health Companies Inc., Hetero, Lupin, Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories Ltd., Sun Pharmaceutical Industries Ltd, and others.

About US:

SNS Insider has been a leader in data and analytics globally with its authentic consumer and market insights. The trust of our clients and business partners has always been at the center of who we are as a company. We are a business that leads the industry in innovation, and to support the success of our clients, our highly skilled engineers, consultants, and data scientists have consistently pushed the limits of the industry with innovative methodology and measuring technologies.

We assist our clients to anticipate industrial, economic, and consumer trends to drive disruptive change by fusing global experience with local information from experts throughout the world. We bring context to strategic and tactical data by bridging approaches based on data science and field research, assisting you in addressing your most pressing problems and spotting possibilities.

Contact Us:

Akash Anand – Head of Business Development & Strategy,

info@snsinsider.com,

Phone: +1-415-230-0044 (US) | +91-7798602273 (IND)